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Abstract
The regulation of body fluid balance is a key concern 
in health and disease and comprises three concepts. 
The first concept pertains to the relationship between 
total body water (TBW) and total effective solute and 
is expressed in terms of the tonicity of the body fluids. 
Disturbances in tonicity are the main factor responsible 
for changes in cell volume, which can critically affect 
brain cell function and survival. Solutes distributed almost 
exclusively in the extracellular compartment (mainly 
sodium salts) and in the intracellular compartment (mainly 
potassium salts) contribute to tonicity, while solutes 
distributed in TBW have no effect on tonicity. The second 
body fluid balance concept relates to the regulation and 
measurement of abnormalities of sodium salt balance and 
extracellular volume. Estimation of extracellular volume 
is more complex and error prone than measurement of 
TBW. A key function of extracellular volume, which is 
defined as the effective arterial blood volume (EABV), 
is to ensure adequate perfusion of cells and organs. 
Other factors, including cardiac output, total and regional 
capacity of both arteries and veins, Starling forces in the 
capillaries, and gravity also affect the EABV. Collectively, 
these factors interact closely with extracellular volume 
and some of them undergo substantial changes in certain 
acute and chronic severe illnesses. Their changes result 
not only in extracellular volume expansion, but in the 
need for a larger extracellular volume compared with 
that of healthy individuals. Assessing extracellular volume 
in severe illness is challenging because the estimates of 
this volume by commonly used methods are prone to 
large errors in many illnesses. In addition, the optimal 
extracellular volume may vary from illness to illness, 
is only partially based on volume measurements by 
traditional methods, and has not been determined for 
each illness. Further research is needed to determine 
optimal extracellular volume levels in several illnesses. For 
these reasons, extracellular volume in severe illness merits 
a separate third concept of body fluid balance.
Key words: Body fluids; Body water; Extracellular volume; 
Hypertonicity; Hypotonicity; Congestive heart failure; 
Hepatic cirrhosis; Sepsis; Nephrotic syndrome
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The regulation and clinical disturbances of body 
fluid and its compartments are traditionally consigned 
to two concepts. The concept of tonicity of body fluids 
is critical in the regulation of the volume of body cells. 
Disturbances in tonicity result from abnormalities in 
the relation between body water and body solute. The 
concept of extracellular volume plays a critical role in 
the regulation of perfusion of body cells and organs. 
Disturbances in extracellular volume result primarily from 
abnormalities in sodium salt balance. Various methods 
for measuring body water and extracellular volume have 
been extensively applied in clinical practice. However, 
precise determination of the optimal body fluid volumes 
encounters difficulties which are greatly accentuated in 
severe illnesses, because several other factors interacting 
with extracellular volume in determining tissue perfusion, 
including cardiac output, capacity of the blood vessels, 
and Starling forces, are significantly altered in these 
illnesses. The aforementioned factors cause changes in 
the extracellular volume and create the need for optimal 
levels of this volume that are higher than those of healthy 
individuals and the need for newer methods for evaluating 
body fluid volumes. Thus, fluid regulation in severe illness 
represents an evolving concept of body fluid balance 
separate from the two traditional concepts. Important 
questions about this third concept remain unanswered 
underscoring the need for further research. 
Roumelioti ME, Glew RH, Khitan ZJ, Rondon-Berrios H, 
Argyropoulos CP, Malhotra D, Raj DS, Agaba EI, Rohrscheib 
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wjgnet.com/2220-6124/full/v7/i1/1.htm  DOI: http://dx.doi.
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INTRODUCTION
Fluid balance is critical in health[1] and disease[2,3]. Its 
management is required in a variety of instances. These 
include stress that healthy individuals may experience 
at certain times, e.g., during intense exercise[4], develo­
pment of various acute or chronic diseases[5­7], and 
complication of the course of several diseases[3,8,9]. Proper 
fluid balance is a key management target for groups 
of individuals experiencing difficulties in maintaining 
normalcy with regard to it, e.g., those with cognition 
disorders[10], the very young[11,12], and the very old[13,14]. 
Less well known is the fact that disorders of fluid balance 
are encountered in conditions common in the general 
population, e.g., obesity[15] or hypertension[16­18].
Distinguishing normal from abnormal fluid balance 
in one’s medical practice can be challenging. The 
diagnosis of fluid balance abnormalities requires the 
informed and reasoned interpretation of clinical and 
laboratory information[14,19]. However, few would argue 
with the contention that the diagnostic accuracy of 
these methods is weak in general[14,19­21] and is further 
complicated by the indiscriminate and inappropriate 
use of terms when expressing aspects of fluid balance. 
For example, the terms “hydration”, “dehydration”, 
and “overhydration” are often loosely used to express 
not one, but two fluid balance concepts, specifically 
body water balance and extracellular volume (ECFV) 
balance[22,23]. The need to distinguish between pure 
water deficit and ECFV depletion has been stressed in 
the literature[24­26]. The use of the term “dehydration” 
to indicate water deficit or ECFV depletion causes 
confusion among health care practitioners[27].
The traditional approach to understanding disorders 
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of fluid balance has been to compare measured or 
estimated TBW and ECFV between the patients being 
studied and the corresponding “normal” values. 
However, this approach has three limitations: First, 
identifying “normal values” is fraught with ambiguity. 
Second, abnormalities in TBW and ECFV often coexist. 
Finally, optimal values of TBW and especially ECFV differ 
considerably between patients with serious illnesses 
vs normal individuals. This last difference justifies the 
introduction of a third approach to fluid balance, namely 
fluid balance in severe illness. Our aim in this report is 
to review the methods of measuring TBW and ECFV, the 
uses and limitations of these methods, and the methods 
of evaluating fluid balance in patients with severe 
illness. 
BODY FLUID BALANCE AS A FUNCTION 
OF WATER BALANCE
Parameters characterizing water balance
The concept of water balance as applied in clinical 
practice refers to the relationship between total TBW 
and body solute. Osmolality, which expresses the total 
solute concentration in a fluid, is the core parameter 
of this concept[28]. The principal physiologic function 
that depends on this first fluid balance concept is 
the maintenance of stable volume of the body cells. 
Stable body cell volume is critical for cell function 
and survival and is based on two membrane­related 
phenomena, active solute transport mechanisms of the 
cell membranes, mainly mediated by sodium­potassium 
ATPase, and high permeability of cell membranes to 
water[29]. This second process has two fundamental 
consequences: (1) Osmolality is equal between the 
intracellular and extracellular compartment in the 
steady state[30]; and (2) the distribution of TBW between 
the intracellular and extracellular compartments is 
determined by the total solute in each compartment[31]. 
Certain solutes dissolved in body fluids are distri­
buted almost exclusively in the intracellular or the 
extracellular compartment, while other solutes are 
distributed in TBW. Changes in the amount of solutes 
distributed in TBW (urea, ethanol, and other alcohols, 
e.g., methanol and propyl alcohol) will lead to parallel 
changes in osmolality of all body fluids, but will not 
cause any change in cell volume. In contrast, changes 
in the amount of solutes distributed, by and large, in 
one of the two major body fluid compartments will lead 
to parallel changes in body fluid osmolality and opposite 
sign changes in cell volumes. For example, a decrease 
in the amount of an extracellular solute causes a 
decrease in body fluid osmolality and an increase in cell 
volume. 
Tonicity is the portion of osmolality contributed by 
solutes distributed in one major body fluid compart­
ment[29]. The terms “hypotonicity” and “hypertonicity” 
should be used to denote, respectively, relative excess 
or relative deficit of water in place of the ambiguous 
terms “overhydration” and “dehydration”. Serum sodium 
concentration ([Na]S) is the most widely applied index of 
tonicity and is accurate except when there is an excess of 
exogenous extracellular solutes, other than sodium salts, 
or in the presence of falsely low laboratory values of [Na]S 
(pseudohyponatremia) resulting from measurement of 
[Na]S by indirect potentiometry when serum water fraction 
is decreased secondary to an increase in serum solid 
(proteins or lipids) concentration[32]. 
Determinants of body fluid tonicity 
The quantitative approach to clinical aspects of the first 
concept of fluid balance is based on the pivotal work 
of Edelman et al[33]. These researchers established the 
relationship between solutes involved in the function of 
tonicity and TBW using dilution of radio­isotopic markers 
in various clinical states potentially associated with 
dystonicity. Their work established the fact that [Na]S 
represents the fraction: Sum of exchangeable sodium 
plus exchangeable potassium over body water[33]. A 
simplified expression of this fraction, used extensively 
in treating disorders of tonicity is as follows: [Na]S = 
(Exchangeable Na + Exchangeable K)/TBW. In this 
fraction, exchangeable sodium represents the extracellular 
solute while exchangeable potassium represents the 
intracellular solute[29]. Abnormal values of the measured 
[Na]S, or serum osmolality, or of serum tonicity calculated 
as the sum of the osmotic equivalents of [Na]S plus 
serum glucose concentration[34], indicate that there is 
a discrepancy between TBW and effective body solute; 
however, they provide no information about excesses or 
deficits of any of the particular determinants of tonicity. 
In fact, TBW may be low, normal, or excessive in patients 
with either hypertonicity[34­37] or hypotonicity[38­43]. Figure 1 
shows changes in extracellular and intracellular volumes in 
euvolemic, hypovolemic and hypervolemic hyponatremia. 
Establishing the presence and degree of excess or 
deficit of the components that determine tonicity is critical 
for the rational management of disorders of tonicity. 
Assessing body water balance is the first step in the 
management of tonicity disturbances. A detailed review 
of the physiology and pathophysiological disturbances of 
body water is beyond the scope of this report; however, 
Schrier has provided an insightful review of this topic[44]. 
Determining whether TBW is abnormal or not in a patient 
presenting with dystonicity requires a comparison of this 
patient’s TBW and the “normal” value of TBW.
Measuring body water
“Normal” TBW values were first established as the 
weight differences between fresh and desiccated animal 
carcasses[45]. Subsequently, TBW was measured by 
dilution of injected markers. Elkington and Danowski 
provide a useful explanation of this methodology[46]. The 
TBW markers most widely applied in research studies 
include tritiated water (3H2O)[47], deuterium oxide­heavy 
water­(2H2O)[48] and antipyrine[49]. Other markers, e.g., 
urea, thiourea and ethanol, have enjoyed only limited 
application. Heavy water does not subject patients to 
Roumelioti ME et al . Fluid balance concepts
4 January 6, 208|Volume 7|Issue |WJN|www.wjgnet.com
radiation and is the main reference method for measuring 
TBW[50,51]. Water labeled with the stable oxygen isotope 
18O (H218O) has also been used to estimate TBW[52]. Both 
tracer hydrogen (2H) and tracer oxygen (18O) exchange 
with various compounds in the body, thereby causing 
small overestimates of body water by dilution of 2H2O 
or measurement of H218O. Hydrogen of water molecules 
exchanges with labile protons in protein molecules, while 
oxygen of water molecules exchanges into inorganic 
pools during formation of ester bonds[53]. Since the rate 
of exchange of 2H with nonaqueous hydrogen slightly 
exceeds the rate of exchange of 18O with nonaqueous 
oxygen in body tissues, body water estimates from 2H2O 
dilution space are approximately 3.5% higher than those 
obtained using H218O[53]. 
Efforts to develop non­invasive measurements of 
TBW applicable to clinical states have applied newer 
techniques that target body composition; these include: 
Dual­energy X­ray absorptiometry (DEXA)[54], air 
displacement plethysmography[55], nuclear magnetic 
resonance spectroscopy[56], and bioelectrical impe­
dance analysis (BIA)[57­59]. This last technique is rela­
tively inexpensive and simple to use. Because of 
these advantages, BIA has been extensively applied 
in clinical settings requiring precise knowledge of the 
state of water balance, e.g., in populations on chronic 
dialysis. The newer methods[54­57] estimate TBW using 
empirical equations derived from comparisons of their 
measurements to measurements made using reference 
methods. The reliability of these newer methods depends 
on the accuracy of certain assumptions made during 
construction of the equations[60,61]. Findings from these 
techniques may disagree in subjects who do not fulfill the 
assumptions on which these equations are based[62].
Comparisons by statistical regression methods of 
measurements of TBW by reference methods to kno­
wn factors affecting body composition has led to the 
development of anthropometric formulas estimating 
TBW as a function of height, body weight, age, gender 
and ethnicity in subjects with normal water balance. 
Of these formulas, three have been extensively used 
in adults[63­65] and one in children[66]. Figure 2 shows 
TBW values derived using the tree formulas for adults, 
which provide comparable values of body water in most 
cases[67]. Estimates from one of these formulas should 
provide more acceptable values of TBW than the older 
methods used to estimate TBW for the computation 
of the volume of the replacement fluids in dystonicity 
states. These older methods accounted only for body 
weight and gender; for example, TBW was computed 
as 0.6 of body weight in men and 0.5 of body weight in 
women. However, the existing anthropometric formulas 
can give misleading results for several reasons. The first 
source of inaccuracy is that they do not account for all 
the determinants of body composition. The degree of 
obesity varies substantially between subjects with the 
same height, age, gender, ethnicity and body weight. 
The anthropometric formulas will compute the same 
value of TBW for all these subjects. However, since body 
fat contains minimal amounts of water, TBW is less in 
obese than lean subjects with the same anthropometric 
characteristics. This is evident in the large standard errors 
of these formulas, which suggest a potential variation 
of several liters of estimates of TBW in subjects with the 
same age, height, weight, and ethnicity, and no water 
balance abnormalities. 
A second source of inaccuracy of the anthropometric 
formulas is the presence of abnormal water balance, 
which creates the potential of even greater error of 
the formulas. Gains or losses of water result in equal 
magnitude gains or losses in body weight. The coef­
ficients assigned to body weight in anthropometric 
formulas can be used to predict the direction of their 
error in subjects with water balance abnormalities. These 
coefficients are substantially lower than 0.5 L/kg in all 
formulas resulting in decreasing values of body water 
content (the fraction TBW over body weight) as weight 
increases and increasing values of water content as 
weight decreases[68]. These changes in water content are 
appropriate for subjects with increasing weight due to 
Ⅰ          Ⅱa          Ⅱb            Ⅲa            Ⅲb              Ⅳa               Ⅳb
ECFV
ICFV30
25
20
15
10
  5
  0 
Figure 1  Body compartment volume (L) in the three categories of hyponatremia. I: Normal state: ECFV = 16 L, ICFV = 24 L, serum sodium concentration ([Na]S) 
= 140 mmol/L. II: Hypovolemic hyponatremia; IIa: Loss of 8 L of isotonic sodium solution: ECFV = 8 L, ICFV = 24 L, [Na]S = 140 mmol/L; IIb: Gain of 8 L of water; 
ECFV = 10 L, ICFV = 30 L, [Na]S = 112 mmol/L. III: Hypervolemic hyponatremia; IIIa: Gain of 8 L of isotonic sodium solution; ECFV = 24 L, ICFV = 24 L, [Na]S = 140 
mmol/L; IIIb: Gain of 8 L of water; ECFV = 28 L, ICFV = 28 L, [Na]S = 120 mmol/L. IV: Euvolemic hyponatremia manifested in the syndrome of Inappropriate ADH 
secretion, which combines water gain and sodium loss[38,39]; IVa: Gain of 8 L of water; ECFV = 19.2 L, ICFV = 28.8 L, [Na]S = 116.7 mmol/L; IVb: Loss of 560 mmol of 
monovalent sodium salt (e.g., NaCl); ECFV = 16 L, ICFV = 32 L, [Na]S = 105 mmol/L. ECFV: Extracellular fluid volume; ICFV: Intracellular fluid volume.
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obesity or decreasing weight due to loss of body fat[68]. 
However, body water content mathematically increases 
in subjects gaining weight because of fluid retention 
and decreases in subjects losing body fluids[69,70]. The 
Chertow anthropometric formula[71] was derived from 
measurements of TBW pre­hemodialysis, when patients 
routinely present with fluid gains. This formula provides 
higher estimates of TBW than the other anthropometric 
formulas[67]. In addition, the Chertow formula accounts 
for one determinant of body composition (diabetes 
mellitus) not included in the other formulas[63­65], and 
contains coefficients that take into consideration inter­
actions between age and gender, age and weight, and 
height and weight[71]. The main drawback of the Chertow 
formula is that it computes TBW for only the average 
fluid gain in the dialysis population that is being studied. 
Johansson et al[72] developed anthropometric formulas 
estimating TBW in peritoneal dialysis patients. Table 1 
shows the anthropometric formulas estimating TBW in 
normal adults, normal children and patients on dialysis.
Determining whether there is water excess or water 
deficit in an individual patient, regardless of tonicity 
issues, can be challenging. Analyses of the components 
of body composition[73] have the potential to reveal 
whether TBW is normal or not. According to Siri’s sim­
plest model of body composition[74], the body has two 
components: Fat and fat­free mass. Body water occurs 
almost exclusively in the fat­free mass component. When 
the water balance is normal, the water content of fat­free 
mass is at or very close to 73%[75­77]. Thus, determining 
whether TBW is within the normal range or not requires 
measurement of both fat­free mass and TBW. 
Methods for measuring TBW and their limitations 
were discussed previously in this report. Fat­free mass 
is routinely measured by BIA or DEXA; however, these 
methods have hidden drawbacks. For example, an 
important assumption of the DEXA measurement of 
fat­free mass is that it contains 73% water[60]. The 
measurement of fat­free mass by reference methods, 
e.g., measurement of total body potassium (TBK) in a 
total body counter[78], is generally not available for routine 
clinical practices. Therefore, measuring TBW accurately 
and determining whether body water content is normal or 
not in individual patients require further research efforts. 
Treatment of dystonicity states
Hyperglycemic crises are associated with hypertonicity 
and severe deficits of body water, sodium, potassium, 
and other electrolytes[79]. The principles and quantitative 
aspects of treatment of these crises are detailed in 
several reports[37,79­81]. Herein we will present the 
principles of management of true (hypotonic) hypon­
atremia[43] and hypernatremia[37].
Extensive guidelines delineating the treatment 
of hypotonic hyponatremia have been published re­
cently[82,83]. Treatment is guided by the severity and 
the pathophysiologic mechanism of hyponatremia[43]. 
Severe cases with profound hyponatremia or symptoms 
attributed to it require infusion of hypertonic saline. The 
infused volume of saline is determined by formulas. The 
Adrogué­Madias formula[41] has been successfully used 
to guide the treatment of hyponatremias. This formula 
calculates the increase in [Na]S after infusion of one liter 
of saline with sodium concentration higher than that 
in the serum and accounts for the original [Na]S, the 
sodium concentration of the infusate, the original TBW 
and the volume of the infusate. A formula for calculating 
the volume of hypertonic saline required to raise [Na]S 
to a desired value, based on the same principles as the 
Adrogué­Madias formula, was published subsequently[84]. 
These two formulas are shown in Table 2[41,84]. 
General therapeutic measures applicable to all 
hypotonic hyponatremias include restriction of fluid in­
take and steps directed towards increasing renal water 
excretion, such as administration of loop diuretics or 
solute (salt tablets, urea)[43]. Specific interventions 
for the management of hyponatremia are predicated 
on the pathophysiologic mechanism of the condition, 
and include: (1) Isotonic saline infusion to restore the 
ability of the kidneys to excrete large volumes of water 
in hypovolemic hyponatremia; (2) vasopressin 2 (V2) 
receptor antagonists to restore the renal diluting capacity 
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Figure 2  Total body water estimates from anthropometric formulas. Estimates of total body water computed by the Hume et al[63], Watson et al[64] and Chumlea et 
al[65] anthropometric formulas for men and women with the same age (40 years) and varying height and weight. AA: African American; C: Caucasians.
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in the Syndrome of Inappropriate Antidiuretic Hormone 
secretion (SIADH); and (3) available specific treatments 
to correct conditions causing hyponatremia[43]. 
The osmotic demyelination syndrome can result 
from too rapid correction of hyponatremia. To prevent 
the development of this syndrome, the general aim of 
treatment is to achieve a maximal increase in [Na]S 
equal to 6 mmol/L over 24­h. Exceptions to this recom­
mendation are cases with persistence of severe clinical 
manifestations from hyponatremia, when an even 
greater rate of increase in [Na]S is required[43]. In certain 
circumstances, foremost after restoration of the urinary 
diluting capacity during correction of hypovolemic 
hyponatremia by adequate volume replacement or after 
correction of SIADH by administration of V2 receptor 
antagonists, dangerous rises in [Na]S can develop. 
Frequent measurement of [Na]S, e.g., every 2 to 4 
h, and, in selected cases, of urine flow rate and urine 
sodium and potassium concentrations, is critical for 
prevention of osmotic demyelination[85]. Prevention of 
formation of large volumes of dilute urine by infusion 
of desmopressin can prevent excessive rises in [Na]S in 
patients in whom correction of the condition causing the 
hyponatremia, e.g., SIADH or hypovolemia, restores the 
urinary diluting mechanism[86,87]. 
Hypernatremia is correctable by infusion of either 
water in the form of 5% dextrose solution or, if hypo­
volemia is present, hypotonic saline. Formulas used 
to calculate the volumes of water or hypotonic saline 
required to obtain the desired decrease in [Na]S are 
based on the same principles as those used to treat 
hyponatremia[37]. Table 2 shows these formulas. Too rapid 
decline in [Na]S increases the risk of severe neurological 
manifestations[37]. 
Clinicians should be aware that in addition to the 
occasional uncertainty associated with estimating TBW 
by means of formulas, formulas for calculating infusion 
volumes for treating dysnatremias carry several other 
potential sources of error[42,43]. These formulas do 
not account for changes in the determinants of [Na]S 
during treatment, such as water and electrolyte losses 
in the urine during treatment[37,84,85], potential release 
of sodium stored in interstitial glycosaminoglycan 
(GAG) networks[88], and changes in intracellular organic 
osmolytes[89]. For these reasons, changes in [Na]S 
during treatment of dysnatremia must be monitored. 
Clarification of the quantitative impact of these other 
determinants on changes in [Na]S during treatment 
of dysnatremias could lead to the development of 
more accurate predictive formulas. However, accurate 
prediction of the magnitude of urinary losses of water, 
sodium and potassium is exceedingly difficult. Monitoring 
of the clinical status of the patients and frequent 
measurements of [Na]S will remain the critical step of 
the treatment of all dysnatremias treated with saline or 
dextrose solutions[43,84,85,88,89]. Water bound to hydrophilic 
surfaces[90] is another elusive factor that can complicate 
the treatment of dystonicity using quantitative tools. 
Table 1  Anthropometric formulas estimating body water
Adults, normal body water values
  Hume and Weyers formulae[6]
     Women: TBW = -5.2702 + 0.44547H + 0.8809W
     Men: TBW = -4.0294 + 0.94786H + 0.296785W
  Watson et al[64] formulae 
     ….Women: TBW = -2.097 +0.069H + 0.2466W
     Men: TBW = 2.447 - 0.0956A + 0.074H + 0.62W
  Chumlea et al[65] formulae 
     Women, African American: TBW = -6.7 - 0.05A + 0.24H + 0.22W
     Women, Caucasian: TBW = -0.50 - 0.0A + 0.8H + 0.20W
     Men, African American: TBW = -8.7 - 0.09A + 0.25H + 0.4W
     Men, Caucasian: TBW = 2.04 - 0.0A + 0.50W - 0.62BMI
Children, normal body water values
  Mellits, Cheek formulae[66]
     Girls, H ≤ 0.8 cm: TBW = 0.076 + 0.0H + 0.507W
     Girls, H > 0.8 cm: TBW = -0. + 0.54H + 0.252W
     Boys, H ≤ 2.7 cm: TBW = -.927 + 0.045H + 0.465W
     Boys, H > 2.7 cm: TBW = -2.99 + 0.209H + 0.465W
Adults, pre-hemodialysis
  Chertow et al[7] formula 
      TBW = 0.07497A - .0767992G + 0.5789498D + 0.27084H - 0.0402056W - 0.00067247W2 - 0.048646 (A × G) + 0.262857 (G × W) + 
     0.00045 (A × W) + 0.008604 (H × W)
Adults, peritoneal dialysis
  Johansson et al[72] formulae 
     Women: TBW = -29.994 - 0.004A + 0.294H + 0.24W
     Men: TBW = -0.759 - 0.078A + 0.92H + 0.2W
…. All patients: TBW = -42.879 - 0.0A + 0.72H + 0.274W
Note that the Watson formula for men has an age term while the Watson formula for women has no age term. Age effects on body water are more 
pronounced in men than in women. This is clearly indicated by the coefficients for age in the Chumlea and Johansson formulas. TBW: Total body water (L); 
H: Height (cm); A: Age (yr); BMI: Body mass index (kg/m2); G: Gender (male = , female = 0); D: Diabetes (present = , absent = 0). 
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However, the extent to which changes in tonicity alter 
the binding of water to hydrophilic surfaces is poorly 
understood and invites further investigation. 
BODY FLUID BALANCE AS A FUNCTION 
OF EXTRACELLULAR FLUID VOLUME
When a body fluid abnormality secondary to a disturbance 
in ECFV is diagnosed, the terms “hypovolemia” and 
“hypervolemia” should be used instead of the ambiguous 
terms “dehydration” of “overhydration”, respectively. The 
regulation of ECFV is a critical body function. 
Determinants of extracellular fluid volume
The three determinants of ECFV are TBW, total intra­
cellular solute, and total extracellular solute. As noted 
earlier, TBW is partitioned between the intracellular 
and extracellular spaces in proportion to the amount 
of solute in each compartment. Changes in TBW 
unaccompanied by changes in solute will cause opposite 
changes in tonicity and in the volumes of body fluid 
compartments. An isolated gain in TBW will cause 
hypotonicity and hypervolemia in both the intracellular 
and extracellular compartments while an isolated loss 
of body water will have exactly the opposite effects. 
Abnormal gains in intracellular solute causing body 
fluid shifts into the intracellular compartment can be 
observed in serious disease states leading to cellular 
sodium gain, such as occur in patients with “sick cell 
syndrome”[91]. Significant losses of intracellular solute, 
i.e., potassium, are associated with fluid shifts into the 
extracellular compartment and hyponatremia[92]. Large 
potassium losses, such as occur secondary to diuretics, 
may be associated with loss of extracellular solute and 
hypovolemia. 
Most clinical ECFV disturbances are caused by 
changes in extracellular solute. Thus, the amount of 
solute in the extracellular compartment is critical in 
any analysis of factors affecting ECFV. Sodium salts, 
including sodium chloride and to a lesser degree sodium 
bicarbonate, constitute 90% or more of the extracellular 
solute. In a real sense, sodium chloride defines ECFV 
and abnormalities in sodium salt balance are the major 
sources of ECFV disturbances[22]. Gain in extracellular 
solutes other than sodium salts (e.g., glucose) can also 
cause ECFV expansion. The kidneys are the end­organ 
that regulate ECFV. Complex circulatory and neuro­
endocrine mechanisms play vital roles in this regulation, 
which has attracted a major part of the research in 
renal transport and excretion mechanisms in health 
and disease[93­95]. Regulation of sodium is a high priority 
renal function. In various clinical conditions stimulating 
the renal mechanisms for sodium retention (e.g., 
hypovolemia, cardiac failure, cirrhosis, etc.), potassium 
balance, acid­base balance and water balance are 
sacrificed to preserve body sodium. Renal tubular sodium 
transport processes account for the largest fraction of 
oxygen consumption in the kidneys[96]. Details of the 
regulation of sodium balance are beyond the scope of 
this report. 
Measuring extracellular fluid volume
Measurement of ECFV entails ambiguities exceeding 
those associated with the measurement of TBW. These 
ambiguities relate to both the concept of ECFV and the 
methods for measuring it. The conceptual difficulty is 
rooted in the definition of extracellular space. Intracellular 
space is defined as the space enclosed within the cell 
membranes and intracellular water is the portion of 
body water in the intracellular space. However, there is 
significant doubt whether all body fluid compartments 
outside the cell membranes should be considered 
as contributing to the ECFV. The fluid compartments 
in question, which were termed by Moore as the 
transcellular fluids[97], include fluids in the gastrointestinal 
tract[98], collagenous connective tissues[99], serous and 
synovial cavities[46], cerebrospinal space[46], lower urinary 
tract[46], and bile ducts [46]. 
Measurement of ECFV by dilution of injected exogenous 
markers, e.g., radioactive compounds[100], added to the 
difficulties. Table 3 lists some of these markers[46,101­113]. 
Several “extracellular” markers penetrate transcellular 
fluids and some, including the commonly used bromide 
Table 2  Formulas for treatment of dysnatremias with saline or water infusions
Hypotonic hyponatremia
  Change in sodium concentration after infusion of 1 L of saline. Adrogué-Madias formula[4]:
  [Na]Final - [Na]Initial = ([Na]Infusate - [Na]Initial)/(TBWInitial + )
  Volume of saline required for a targeted serum sodium concentration[84]:
  VInfusate = TBWInitial × ([Na]Targeted - [Na]Initial)/[Na](Infusate - [Na]Targeted)
Hypernatremia
  Volume of D5/W required for a targeted serum sodium concentration[7]:
  VInfusate = TBWInitial × ([Na]Initial - [Na]Targeted)/[Na]Targeted
  Volume of hypotonic saline required for a targeted serum sodium concentration[7]:
  VInfusate = TBWInitial × ([Na]Initial - [Na]Targeted)/([Na]Targeted - [Na]Infusate)
[Na]Final: Final serum sodium concentration after infusion of 1 L of saline with a sodium concentration 
higher than the initial serum sodium concentration; [Na]Initial: Initial serum sodium concentration; [Na]Infusate: 
Sodium concentration in the infused saline; TBWInitial: Initial volume of body water; VInfusate: Volume of 
infused saline or dextrose required for a targeted change in serum sodium concentration; [Na]Targeted: 
Targeted value of serum sodium concentration.
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salts, enter partially into the intracellular compartment[46]. 
Consequently, there are substantial differences in the 
estimates of ECFV between these markers[46]. 
Recently, several new technologies for measuring 
ECFV have been developed[114]. Table 4 shows the principal 
techniques, which fall into the following three categories: 
(1) methods based on body composition, including 
BIA[115­121] or bioelectrical impedance vector analysis 
(BIVA)[122,123], DEXA[124­132], and magnetic resonance 
imaging (MRI)[133]; (2) simultaneous measurement of 
TBK in a total body counter measuring stable potassium 
(40K) and TBW usually by 2H2O dilution[134­136]; and (3) 
estimation of glomerular filtration rate (GFR) using 
exogenous markers with extracellular distribution[137­147]. 
The ECFV value is computed in the third category by either 
constant infusion[138], or, more often, a single injection[139] 
of the exogenous GFR marker. In the case of a single 
injection, the theoretical equilibrated initial concentration 
of the marker in the extracellular fluid is calculated by 
extrapolating its plasma disappearance curve to zero time 
(time of infusion of the marker)[139]. 
The methodologies for measuring TBW and ECFV by 
these newer techniques were developed by comparing 
their performance to measurements from the older 
dilution techniques, mostly the 2H2O and bromide dilu­
tion techniques[116,117,126,130,134,148­156]. Figure 3 shows 
average ECFV values obtained by the older dilution 
techniques (Table 3) and several frequently used newer 
techniques (Table 4). The values resulting from the most 
commonly used newer techniques (BIA, DEXA) are, in 
most cases, close to those based on chloride or bromide 
space. Equations predicting normal ECFV values from 
simple anthropometric measurements, for example as 
a fraction of body weight, were developed using ECFV 
measurements by one of the newer methods[144,157]. 
However, these equations are not accurate in patients with 
ECV disturbances. Finally, techniques for measuring ECFV 
in diseased organs or tissues, for example in malignant 
tumor­bearing organs, have also been developed[158­160]. 
Clinical applications of extracellular fluid volume 
estimates 
The main clinical application of measurements of 
ECFV is in conditions requiring precise management of 
excesses or deficits of this volume. To quantify ECFV 
excess, Chamney et al[50] measured TBW by 2H2O 
dilution, ECFV by NaBr dilution, and body fat by DEXA 
and air­displacement. These investigators developed 
a quantitative model of body fluids containing three 
compartments: Normally hydrated lean tissue, normally 
hydrated adipose tissue, and excess fluid. Chronic 
dialysis for end­stage kidney disease represents an 
example of Chamney’s three­body fluid compartment 
approach. One of the main aims of the prescription of 
hemodialysis is achieving “dry weight” by computing 
prior to each hemodialysis session the volume of fluid 
that should be removed to return ECFV within its 
normal range[161]. Although clinical criteria for ECFV 
excess or deficit are useful in monitoring the overall 
state of health of hemodialysis patients, they have 
low positive and negative predictive values and carry 
the risk of excessive volume removal and hypotension 
during a hemodialysis session. DEXA has been used to 
evaluate ECFV in a small number of studies[162]. BIA and 
BIVA studies are simple, technically easy to conduct, 
and inexpensive. Studies conducted in various parts of 
the world have provided evidence that measurements 
of ECFV by BIA or BIVA improve the management of 
fluid balance in hemodialysis patients[163­170]. 
Hyperglycemic crises represent another clinical 
state in which ECFV changes, along with changes in 
the relationship between TBW and body solute, cause 
severe clinical manifestations and play an important 
role in the prescription of fluid management[37]. ECFV 
changes occur during both development and treatment 
of severe hyperglycemia and differ between subjects 
with preserved and severely impaired renal function. 
The increase in extracellular solute during development 
of hyperglycemia causes intracellular water to shift into 
the extracellular compartment. This osmotic fluid shift, 
Table 3  Measurement of extracellular volume by tracer 
dilution
Extracellular marker Ref.
Inulin [0]
Sucrose [02]
Thiosulfate [0,04]
Mannitol [05]
Radiosulfate (S5) [06,07]
Bromide [08,09]
Radiochloride (Cl8, Cl6) [09,0]
Stable chloride (Cl5) []
Radiosodium (Na24) [2]
Thiocyanate []
Table 4  Measurement of extracellular volume by newer 
methods
Methodology Ref.
Methods evaluating body composition
  Bioelectrical impedance, bioelectrical impedance vector 
  analysis
[5-2]
Dual-energy X-ray absorptiometry [24-2]
  Magnetic resonance imaging []
Methods measuring total body water and intracellular 
volume
  Simultaneous measurement of total body water and 
potassium
[4-6]
Methods using GFR markers
  Inulin [8,9]
  Polyfructosan [40]
  5cromium ethylenediamine tetra-acetic acid (5Cr-
  EDTA)
[4-4]
  Iohexol [44]
  Technetium diethylene triamine penta-acetic acid 
  (99mTC-DTPA)
[45,46]
  Iothalamate [47]
GFR: Glomerular filtration rate.
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which affects the estimation of the serum tonicity[171], 
may cause volume overload symptoms in patients 
with advanced renal failure[172]. The calculation of the 
magnitude of this shift requires knowledge of the amount 
of glucose added to the extracellular compartment, in 
addition to Edelman’s three determinants of [Na]S, which 
include body sodium, body potassium and TBW[173,174]. 
The total amount of glucose in the body fluids is the 
product of the volume of distribution of glucose times the 
serum glucose concentration[37]. 
Calculations of body fluid spaces made after a 
single glucose injection in normal individuals reported a 
glucose volume of distribution that was within the range 
of normal ECFV values[175­177]. Insulin is usually the only 
treatment required for hyperglycemia in oligoanuric 
patients in whom correction of hyperglycemia reverses 
both hypertonicity and ECFV expansion[172]. The reciprocal 
changes in [Na]S and serum glucose concentration 
during treatment of oligoanuric hyperglycemia with 
insulin only allow the calculation of the fraction ECFV/
TBW at normoglycemia[178]. Calculation of this fraction 
in hyperglycemic patients at their “dry weight” yielded 
ECFV/TBW values within the normal range[178].
Both ECFV changes and tonicity differ in hyperglycemic 
patients with preserved renal function[81,174,179]. These 
patients manifest osmotic diuresis secondary to glycosuria 
during development of hyperglycemia. The fluid loss 
from osmotic diuresis causes ECFV contraction and 
rise in tonicity far exceeding the rise from extracellular 
glucose gain. ECFV losses persist during treatment 
if glycosuria persists[79]. In most cases, treatment of 
hyperglycemia in this patient group requires, in addition 
to insulin, infusion of large volumes of hypotonic saline 
and potassium salts and close monitoring of clinical status 
and laboratory values[37]. The volume and composition 
of the replacement solutions is determined empirically 
based on clinical manifestations and laboratory values. 
Selected cases where body weight measurements were 
recorded immediately before and during a hyperglycemic 
crisis allow more precise calculation of the volume and 
composition of the replacement solutions, but still require 
close monitoring[81]. 
In addition to chronic dialysis and hyperglycemia, 
ECFV abnormalities and the need to monitor ECFV and 
its changes during treatment have been investigated in a 
variety of chronic and acute illnesses[128,154,180­187]. Finally, 
another example of the potential clinical applications of 
ECFV and TBW measurements is in determining body 
composition. The components of body composition, 
particularly muscle mass and body fat, are major de­
terminants of morbidity and mortality in the elderly, 
as well as in patients with various acute and chronic 
illnesses[188,189]. Wang et al[190] developed sophisticated 
mathematical models of body composition using as their 
major parameter the ratio of extracellular to intracellular 
water. Measuring TBW and ECFV provides a reliable 
reference method for body composition analysis.
Limitations of extracellular fluid volume estimates
The efficacious application of measurements of ECFV in 
clinical practice relies on precise estimates of the normal 
values. Determination of the normal ECFV values has 
encountered significant limitations. The first limitation 
relates to the determination of the precision of ECFV 
measurement, which is established by frequent serial 
measurements[191]. Burke and Staddon measured 
repeatedly over a six­week period TBW by 3H2O 
dilution and ECFV by radiosulfate dilution in 10 healthy 
subjects[192]. These authors calculated a mean precision 
value of 2.63 L for TBW and 1.11 L for ECFV. The presence 
of disease raises an additional challenge to the precision 
of the ECFV measurements. Below we discuss the 
precision of three methods which have received extensive 
clinical applications: Namely chloride or bromide dilution, 
measurement of TBK and TBW, and BIA. 
Estimates of ECFV based on chloride, or more 
frequently bromide, dilution are calculated as the fraction 
“amount of marker in the body” over “the equilibrated 
concentration of this marker in the extracellular fluid” 
and are routinely corrected for Gibbs­Donnan equilibrium 
and intracellular penetration of the markers[193]. The 
Gibbs­Donnan equilibrium states that due to electrostatic 
forces, the concentration of a crystalloid anion is higher 
in interstitial fluid than in serum, which is rich in colloidal 
anions (i.e., proteins)[29]. The extracellular chloride 
or bromide concentration is calculated by multiplying 
the serum concentration by an empiric Gibbs­Donnan 
coefficient, which is usually 1.050[193]. The magnitude of 
the error from this calculation in subjects with low plasma 
protein level or elevated interstitial protein concentration 
is unknown. 
The calculated estimates of ECFV by bromide or 
chloride dilution are also corrected for intracellular 
penetration of the ECFV index by a reducing coefficient, 
usually 0.90[193]. Penetration of reference extracellular 
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Figure 3  Average extracellular fluid volume estimates expressed as 
percentages of total body water. Ⅰ-Ⅴ: Tracer dilution estimates[46]; Ⅰ: 
Sucrose, thiosulfate; Ⅱ: Mannitol, sulfate; Ⅲ: Bromide, chloride; Ⅳ: Sodium; Ⅴ: 
Thiocyanate; Ⅵ-Ⅶ: Newer techniques; Ⅵ: Dual-energy X-ray absorptiometry[130]; 
Ⅶ: Bioelectrical impedance[115]; Ⅷ: Simultaneous determination of total body 
potassium and total body water[195]; Ⅸ, Ⅹ: Glomerular filtration rate markers; Ⅸ: 
Inulin[139]; Ⅹ: Iothalamate[147]. ECFV: Extracellular fluid volume; TBW: Total body 
water.
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markers into the transcellular or intracellular compart­
ment differs between healthy and severely ill subjects. 
Cunningham et al[194] analyzed the intracellular electrolyte 
composition of deltoid muscles in 7 normal subjects and 
13 patients with various severe illnesses. Intracellular 
chloride concentration was 4.1 ± 1.5 mmol/L in the 
healthy subjects and 8.8 ± 3.6 mmol/L in the patients. 
Corresponding extracellular chloride concentrations were 
104.4 ± 5.7 and 106.7 mmol/L respectively. Schober 
et al[195] measured TBW by 3H2O dilution and ECFV 
by radiobromide dilution in 10 normal subjects and 
38 critically ill patients. TBW values were comparable 
between the two groups (536 ± 56 mL/kg in the healthy 
subjects and 505 ± 68 mL/kg in the critically ill patients). 
In contrast, bromide space as a fraction of body water 
was substantially higher in the critically ill patients (0.83 
± 0.17) than in the normal subjects (0.46 ± 0.04). 
These findings are consistent with substantially higher 
penetration of bromide into the intracellular compartment 
in critically ill patients than in normal subjects and 
raise serious concerns about the validity of ECFV 
measurements by bromide space in critically ill subjects.
The calculation of ECFV made by combining TBK 
and TBW values assumes that intracellular and extra­
cellular potassium concentrations are constant, usually 
152 and 4 mmol/L, respectively[136]. The equation 
for calculating ECFV is as follows: ECFV = (152 × 
TBW∣TBK)/148[136,193]. Calculations of ECFV using 
this equation provided a reasonable agreement with 
calculations based on bromide space in the large nu­
mber of subjects studied by Silva et al[193], with diff­
erences being more pronounced in obese subjects. 
ECFV calculations made using equations that combine 
TBW and TBK measurements will be subject to errors 
in subjects whose intracellular potassium concentration 
differs substantially from 152 mmol/L. Subjects with 
dystonicity in whom ECFV measurements may be 
required[184], have an abnormal intracellular potassium 
concentration. Certain categories of patients with se­
vere illness, e.g., uremic patients, may also have low 
intracellular potassium concentration[196]. 
The principles and limitations of measurements of TBW 
and its compartments by BIA have been reviewed[61,118,167]. 
As stated above, BIA is widely used to investigate the 
status of body fluids in patients on dialysis. In patients 
undergoing hemodialysis, TBW measurements by BIA, 
which are used in the calculation of ECFV estimates, 
differed from 2H2O­based measurements by a margin 
of ­3.4 to 20.3 L in one report[197]. Another report found 
gross underestimation of TBW by BIA in a hemodialysis 
patient with extreme ascites and hydrothorax[165]. In a 
study comparing measurements of TBW in hemodialysis 
patients by BIA and 2H2O, Chan et al[198] concluded 
that BIA either underestimates systematically TBW or 
overestimates systematically intracellular water and that 
the differences between reference and BIA measurements 
of TBW increase as comorbidities increase. 
Another difficulty in measuring ECFV is establishing 
normal values. This process is complicated by various 
factors. In studies by Silva et al[136,199], the fraction 
ECFV/TBW increased progressively with age in men, 
while both African American men and women had 
higher values of this fraction compared to subjects 
from other ethnic backgrounds. Several studies have 
confirmed that women have higher ECFV/TBW values in 
comparison to age­matched men[114,200­202]. Children have 
substantially different ECFV/TBW values than adults[203], 
and obese children have higher ECFV/TBW values than 
non­obese children[151]. These facts underscore the need 
for establishing normal ECFV values that are specific for 
gender, age, ethnicity and degree of obesity. 
The importance of estimates of ECFV in various 
disease states, the various methods that are available 
for measuring ECFV, and the limitations and costs of 
these methods create the need to choose the best 
method of measurement. Shepherd et al[204] compared 
recently various methods of analyzing body composition 
in terms of cost, compliance, infrastructure, precision, 
quality control, training, trueness, and safety. The 
major limitation of all methods for measuring ECFV is 
encountered during severe acute or chronic illnesses. 
Several illnesses lead to both hypervolemia producing 
clinical manifestations and uncertainty about the desired 
values of ECFV. For these reasons, the challenge of 
optimal ECFV in severe illness merits a separate analysis 
as a fluid balance concept and is addressed in the next 
section.
BODY FLUID BALANCE IN SEVERE 
CHRONIC OR ACUTE ILLNESS
Concept and principles of management of fluid balance 
in illness 
Disturbances of body fluid balance are cardinal mani­
festations of many severe acute or chronic illnesses[205]. 
Precise management of these disturbances is critical[206]. 
Fluid management must address both repletion of 
deficits and avoidance of excesses[207] and requires 
understanding of the regulation and measurement of 
TBW and particularly ECFV. Adequate blood perfusion 
of organ systems is essential and is an indispensable 
role of ECFV. Normal cell function and survival require 
an uninterrupted supply of oxygen and nutrients, and 
removal of carbon dioxide and metabolic by­products. It 
has long been recognized that the optimal value of ECFV 
in critical illness may differ from a “normal” value[208]. 
The term “obligatory edema” was used in the past to 
denote the need for an expanded ECFV in patients with 
hepatic cirrhosis, ascites and hypoalbuminemia. The 
term “effective blood volume” was coined by Peters 
to indicate the need for supranormal blood volume in 
certain disease states[209,210]. More recently, the term 
effective arterial blood volume (EABV) has been used to 
indicate the state of organ perfusion[95].
EABV is affected by several physiologic functions 
and biochemical parameters in addition to ECFV. 
Parameters related to either the composition of the 
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blood, for example blood hemoglobin concentration and 
arterial blood gases, or the metabolic needs of diseased 
cells, are not directly correlated with ECFV. There are, 
however, several factors influencing EABV that interact 
directly with ECFV. Changes in these factors in disease 
states create the need for ECFV values that exceed 
normal values. Table 5 shows factors affecting organ 
perfusion that are interacting with ECFV[211,212]. A brief 
discussion of these factors follows.
ECFV directly defines the plasma volume. Schrier 
explored the interaction between cardiac function, 
arterial tone, and ECFV regulation as well as the factors 
affecting this relationship[213]. Starling forces in the 
blood capillaries and surrounding interstitial space 
dictate fluid exchanges between the intravascular 
and interstitial spaces. The importance of an effective 
capillary endothelial barrier to albumin transfer from 
the intravascular into the interstitial compartment is 
exemplified by patients who lose this barrier. Such 
patients require infusion of enormous volumes of 
albumin­containing fluid to maintain their intravascular 
volume[214]. 
The effects of gravity on EABV and ECFV were 
studied during space flights. Absence of gravity causes 
large transfer of fluids from peripheral body parts (e.g., 
limbs) into the central blood volume and decreases in 
the blood levels of vasopressin, renin and aldosterone, 
and causes profound diuresis of water and sodium 
salts[215­217]. Gravity and “head­out” water immersion 
have similar effects on EABV and ECFV[218]. This 
last observation may have clinical implications. The 
interactions between the factors indicated in Table 5 is 
the source of different optimal ECFV values in health 
and severe illness. 
The aim of fluid management in severe illness is 
prevention of both organ hypoperfusion and circulatory 
overload. The methodology for evaluating EABV and 
determining whether clinical manifestations of low EABV 
are responding to volume replacement in critically ill 
patients is complex. The response of EABV to fluid 
challenges is monitored by a variety of invasive static 
(stroke volume, cardiac output, cardiac index) and 
dynamic (stroke volume variation, pulse pressure 
variation, change in the fraction “stroke volume”/”cardiac 
index”) parameters[219]. The uses and limitations of the 
patient’s history and clinical examination, chest X­ray 
and echocardiography, continuous dynamic evaluation 
of circulatory parameters during fluid administration, 
certain biochemical values, and BIVA in evaluating 
body fluid status were reviewed by Kalantari et al[207]. 
Adequate perfusion of the kidneys and prevention of 
acute kidney injury (AKI), which is both frequent in 
this clinical setting and an independent risk factor for 
mortality and prolonged hospital stay[220­222], is a main 
target of this fluid management. Fluid management 
efforts in critical illness should be directed towards the 
interactions of systemic and renal hemodynamics, the 
preservation of the renal microcirculatory blood flow[223], 
and the determination of indications for mechanical fluid 
removal[224].
The mechanisms that underlie fluid imbalance and 
their treatment vary depending on the nature of cri­
tical illnesses. Palmer et al[95] analyzed the general 
mechanisms leading to decreased EABV and target ECFV 
values that are higher than normal. These mechanisms 
include: Fluid trapping in the interstitium or a preformed 
body cavity; reduced serum oncotic pressure; and 
vascular disturbances, e.g., altered capillary filtration 
pressure due to low cardiac output, increased venous 
resistance, or endothelial dysfunction. 
The clinical states discussed subsequently in this 
report illustrate the pathophysiologic mechanisms 
and the principles of fluid management in critically ill 
patients. The management of these conditions should 
address, in addition to ECFV, correction of abnormalities 
in the other factors specified in Table 5. However, ECFV 
estimates made using traditional methods have a 
limited role in this management. The clinical states we 
have chosen to illustrate the concepts of fluid imbalance 
secondary to EABV disturbances in severe illness include 
congestive heart failure (CHF), hepatic cirrhosis, and 
sepsis. Finally, nephrotic syndrome represents a unique 
state of disturbed fluid balance. The pathogenesis of 
fluid imbalance in nephrotic syndrome involves both 
a reduced EABV and primary sodium salt retention by 
the kidneys. The mechanisms of volume retention in 
nephrotic syndrome will be discussed briefly.
Congestive heart failure 
Fluid retention characterizes the course of CHF, causes 
serious clinical manifestations, and is one of its main 
therapeutic targets. A decrease in cardiac output is the 
primary cause of fluid retention in CHF secondary to left 
ventricular failure (Table 5). Palmer et al[95] reviewed 
the complex mechanisms sensing decreased EABV 
and the effector mechanisms of renal retention of salt 
and water in CHF. The Frank­Starling law of the heart 
states that the stroke volume increases as end­diastolic 
volume increases when all other factors affecting 
myocardial performance are unchanged[225]. In early­
compensated stages of CHF, elevated left ventricular 
end diastolic volume secondary to both decreased 
Table 5  Factors affecting cell- and organ-perfusion (effective 
arterial blood volume)
Blood volume
  Red blood cell mass
  Plasma volume
Cardiac output
Vascular capacity
  Arterial resistance, total
  Arterial resistance, regional
  Venous capacity
Starling forces in blood capillaries
Endothelial barrier integrity
Gravity
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cardiac performance and ECFV expansion leads to an 
increase in stroke volume and restoration of cardiac 
output. Figure 4 compares the fraction ECFV/TBW in 
elderly subjects with relatively compensated CHF and 
healthy controls[226]. At this relatively early stage of 
CHF, ECFV/TBW was higher than normal. It is not clear 
whether the higher than normal ECFV in this stage of 
CHF is beneficial in the long term or not. 
As CHF progresses, low EABV leads to progressive 
renal retention of salt and water[227], which causes ECFV 
expansion and progressive distention of the myocardium 
with adverse effects on cardiac performance[228]. 
Determining the optimal level of ECFV and maintaining 
the patient at that level are major management goals. 
Mechanisms of salt and water retention may differ 
between right and left ventricular failure[229]. Myocardial 
dysfunction in valvular disease and “high­output” 
cardiac disease represent other categories of CHF in 
which the optimal levels of ECFV may differ from those 
in left ventricular failure. 
Fluid overload therapy can be insufficient in many 
patients hospitalized with CHF. Incomplete fluid removal 
during the hospital stay coupled with the limitations of 
weight­based management to identify the recurrence 
of fluid retention post discharge leads to symptomatic 
elevated intracardiac right and left­sided filling pressures. 
In these patients, vigorous and timely reduction of the 
elevated filling pressures leads to improved prognosis, 
fewer hospitalizations and better outcomes. However, 
prevention of both symptomatic ECFV expansion and 
lower than optimal ECFV in CHF is important. In dilated 
CHF, forward flow is optimal at near­normal filling 
pressures, with minimized mitral regurgitation[230]. In 
cases of acute CHF with persistent clinical manifestations, 
such as respiratory distress and impaired systemic 
perfusion, right heart catheterization is indicated. Fluid 
management must incorporate a thorough clinical 
patient evaluation, use of appropriate diuretics, frequent 
follow­up, and daily weight measurement[231]. Despite 
these measures, re­admissions are not prevented; thus, 
multiple approaches for monitoring outpatient fluid 
balance are being explored.
Natriuretic peptide biomarkers (BNP, B­type natri­
uretic peptide, NT­pro­BNP, N­terminal pro­B­type 
natriuretic peptide) are increasingly being used to 
diagnose and estimate the severity of CHF as well as for 
population screening purposes. Many other biomarkers 
have been implicated in CHF (markers of inflammation, 
oxidative stress, vascular dysfunction, and myocardial 
and matrix remodeling). Furthermore, biomarkers of 
myocardial fibrosis, soluble ST2 receptor, and galectin­3 
are predictive of hospitalization and death and may 
provide supplemental prognostic value to BNP levels in 
patients with CHF[231]. All these biomarkers have been 
used in assessing fluid balance status in patients with 
CHF.
BIVA has also been applied in assessing fluid balance 
status in patients with CHF[130]. Valle et al[232] tested 
the hypothesis that achievement of adequate ECFV 
status with intensive medical therapy, modulated by 
combined BIVA and BNP measurement, optimizes the 
timing of discharge and improves the clinical outcomes 
of patients admitted with acutely decompensated heart 
failure (ADHF). Three hundred patients admitted for 
ADHF underwent serial BIVA and BNP measurements. 
Therapy was titrated to reach a BNP value < 250 pg/
mL. Patients were categorized as early responders 
(rapid BNP fall below 250 pg/mL); late responders (slow 
BNP fall below 250 pg/mL, after aggressive therapy); 
and non­responders (BNP persistently > 250 pg/mL). 
Worsening of renal function was evaluated during 
hospitalization. Death and re­hospitalization were 
monitored with a 6­mo follow­up. This study confirmed 
the hypothesis that serial BNP/BIVA measurements 
help to achieve adequate fluid balance status in 
patients with ADHF and can be used to drive a “tailored 
therapy”, allowing clinicians to identify high­risk patients 
and possibly to reduce the incidence of complications 
secondary to fluid management strategies.
The combined use of BNP and BIVA for assessing and 
managing fluid overload, distinguishing cardiogenic from 
non­cardiogenic dyspnea, and improving management 
of CHF patients in Emergency Departments was tested 
in another report as well[233]. This randomized controlled 
trial was designed to investigate whether fluid status 
monitoring with an automatically generated wireless 
CareAlert notification can reduce all­cause death and 
cardiovascular hospitalizations in a CHF population, 
compared with standard clinical assessment[234]. The 
investigators found that fluid status telemedicine alerts 
did not significantly improve outcomes in patients 
with advanced CHF and implantable cardioverter defi­
brillators (ICDs). The problem of adherence to treat­
ment protocols by physicians and patients might be 
compromising advances in the telemedicine field[235].
ECFV/TBW fraction
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Figure 4  The fraction extracellular volume over total body water in elderly 
subjects with relatively compensated congestive heart failure and healthy 
controls. Mean values ECFV/TBW in the study of Sergi et al[228]. The mean 
ejection fraction of elderly patients with relatively compensate congestive heart 
failure (CHF) and absence of pleural effusion was 40%. Total body water (TBW) 
was measured by 2H2O dilution and extracellular volume (ECFV) by bromide 
dilution. The fraction ECFV/TBW was significantly higher in subjects with CHF.
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The term Cardio­Renal Syndrome (CRS) defines 
disorders of the heart and kidneys whereby “acute or 
chronic dysfunction in one organ may induce acute 
or chronic dysfunction of the other”[236]. CRS requires 
a tailored approach to manage a patient’s underlying 
pathophysiology while optimizing the patient’s clinical 
picture and thus providing better outcomes. Precise 
prescription of fluid removal by diuretics or extracorporeal 
therapies is a key element of this approach. Adequate 
monitoring of fluid balance is essential for preventing 
worsening of renal function or other complications while 
delivering these therapies. Monitoring of extravascular 
fluid in the lungs by ultrasonography is helpful in fluid 
management[237]. The range of optimal ECFV values 
appears to be very narrow in patients with CHF. Hyper­
volemia results in myocardial stretching and decom­
pensation, whereas hypovolemia leads to low EABV that 
can result in organ damage. Therefore, in cases with CRS 
the “5B” approach has been suggested: Balance of fluids 
(reflected by body weight), blood pressure, biomarkers, 
BIVA, and blood volume[236]. 
It has traditionally been presumed that patients with 
CHF benefit from a low­sodium diet. A recent review 
attempted to provide insight into the currently available 
evidence base for the effects of dietary sodium restriction 
in patients with chronic CHF. This review concluded 
that both observational and experimental studies have 
shown mixed results and that the effects of a low­sodium 
diet on clinical outcomes in patients with CHF remain 
controversial and unclear[238]. However, the fact remains 
that most hospitalizations for CHF are related to sodium 
and fluid retention. Recent research suggests that not 
all sodium is distributed in the body solely as a free 
cation, but that some sodium is also bound in different 
tissues to large interstitial GAG networks that appear to 
have important regulatory effects on ECFV. In CHF, high 
sodium intake and neurohumoral alterations disrupt 
GAG structure, leading to loss of the interstitial buffer 
capacity for sodium and disproportionate interstitial fluid 
accumulation. Moreover, a diminished GAG network 
increases vascular resistance and interferes with 
endothelial nitric oxide production. Improved imaging 
modalities should help in the assessment of interstitial 
sodium levels and endothelial glycocalyx integrity. 
Furthermore, several therapies have been proven to 
stabilize interstitial GAG networks, e.g., hydrocortisone, 
sulodexide, dietary sodium restriction, spironolactone). 
Hence, better understanding of this new sodium 
“compartment” might improve the management of 
CHF[239].
Detailed guidelines for the diagnosis and treatment 
options of the various forms of CHF (acute or chronic, 
with reduced or not­reduced ejection fraction) are 
available[231,240]. The patient who presents with suspected 
CHF should be assessed by clinical history and detailed 
physical examination. Chest X­ray, electrocardiogram 
and blood levels of natriuretic peptides are always useful. 
The next step is an echocardiogram. If CHF is confirmed, 
its etiology should be determined and appropriate 
treatment initiated. At the end of these guidelines the 
authors discuss the missing pieces of information in the 
existing literature and offer thoughtful recommendations 
for future work. Since there is no exact method for 
estimating optimal ECFV in patients with CHF, future 
studies should address this knowledge gap. 
Cirrhosis-ascites-hepatorenal syndrome
Decreased EABV is a cardinal feature of cirrhosis in 
which changes in multiple factors activate the mech­
anisms of sodium retention and ECFV expansion. 
Factors that lead to decreased EABV in cirrhosis are 
listed in Table 5 and include: Increase in overall arterial 
and venous capacity, decrease in Starling forces, and, 
in late stages of cirrhosis, decrease in cardiac output. 
The decrease in arterial and venous resistance is a 
strong stimulus for increased ECFV. Advanced cirrhosis 
is characterized by portal hypertension, arteriovenous 
fistulae, peripheral vasodilatation, and sequestration of 
plasma volume in the abdominal cavity and splanchnic 
venous bed[241]. The “arterial vasodilation theory” is the 
most widely accepted explanation for the expansion 
of ECFV in cirrhotic patients[242]. An alternative theory, 
designated the “hepatorenal reflex hypothesis”, 
suggests that vascular bed vasodilatation in cirrhosis is 
a consequence of the shunting of blood from the portal 
to the systemic circulations rather than an etiology for 
volume overload; however, further research is required 
to support this hypothesi[243]. 
The widely recognized causes of vasodilatation in 
cirrhosis are: (1) Increased production or increased 
activity of vasodilating factors by hepatocytes and stellate 
cells (mainly nitric oxide, carbon monoxide, prostacyclin 
and endogenous cannabinoids); (2) reduced response to 
vasoconstrictor factors; (3) mesenteric neoangiogenesis; 
(4) compromise of cardiac output as cirrhosis progresses 
probably due to cirrhotic cardiomyopathy; and (5) 
systemic inflammatory response with increased pro­
duction of pro­inflammatory cytokines (IL­6, TNF­α) 
and vasodilating factors due to translocation of bacteria 
and their products across the intestinal barrier to 
mesenteric lymph nodes[244­247]. In addition, markers 
of oxidative stress such as oxidized albumin have been 
shown to increase in decompensated cirrhosis[242]. The 
exact cellular and molecular mechanisms implicated in 
the phenomenon of bacterial translocation in cirrhosis 
have not been fully elucidated[246]. Hypoalbuminemia, 
another feature of advanced cirrhosis, decreases 
intracapillary colloid­osmotic forces and increases fluid 
translocation from the intravascular into the interstitial 
compartment leading to further decreases in EABV. 
Circulatory abnormalities in cirrhosis define the stages 
of progression of cirrhosis that ultimately culminate in 
hepatorenal syndrome (HRS). Cardiac output is not a 
cause of clinical manifestations in early compensated 
stages, but is increased in advanced cirrhosis, and may 
decrease in its later stages and thus contribute to the 
decreased EABV. Cirrhotic vasodilatation stimulates 
the arterial stretch receptors in the carotid sinus and 
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aortic arch, producing a baroreceptor response and 
activation of compensatory vasoconstricting mechanisms 
including the renin­angiotensin­aldosterone system, 
the sympathetic nervous system, and the non­osmotic 
hypersecretion of vasopressin[248]. Stimulation of these 
systems contributes to maintenance of blood pressure by 
modulating decreases in the systemic vascular resistance 
and increasing cardiac output[248]. 
The so­called “hyperdynamic syndrome” in cirrhosis 
is a consequence of portal hypertension and involves 
complex humoral and neural mechanisms. This syndrome 
is hemodynamically characterized by high cardiac output, 
increased heart rate and total blood volume, reduced total 
systemic vascular resistance and normal or decreased 
blood pressure[245]. Arterial blood volume is shunted to 
the splanchnic vessels at this stage, while the central 
arterial blood volume (heart, lungs, and central arterial 
tree blood volume) is often decreased[245]. At a later stage, 
the hyperdynamic syndrome leads to cardiac dysfunction 
(cirrhotic cardiomyopathy), pulmonary dysfunction 
(hepatopulmonary syndrome) and renal dysfunction 
(HRS), in addition to reduced survival[249]. 
The function of the cardiovascular system is disturbed 
in cirrhosis due to decreased vascular reactivity and a 
universal endothelial and autonomic dysfunction[249]. 
Cirrhotic cardiomyopathy is characterized by impaired 
myocardial contractility with systolic and diastolic 
dysfunction in combination with electromechanical 
abnormalities, such as prolongation of the Q­T interval, 
in the absence of any other cardiac disease[249]. Some 
degree of diastolic dysfunction may be present in > 50% 
of cirrhotic patients regardless of the presence or extent 
of ascites. No correlation has been found between HRS 
and diastolic dysfunction[242]. A study of the role of cardiac 
abnormalities in the pathogenesis of circulatory and renal 
dysfunction in cirrhosis[250] concluded that: (1) Diastolic 
dysfunction is frequent, but mild in most cases and does 
not increase the pulmonary artery pressure to abnormal 
levels. This may be due to the central hypovolemia of 
cirrhosis and probably accounts for the lack of symptoms 
associated with this condition; (2) diastolic dysfunction 
is unrelated to circulatory dysfunction and ascites; and 
(3) in cirrhosis, there is a lack of response of the left 
ventricular systolic and chronotropic function to peripheral 
arterial vasodilatation and activation of the sympathetic 
nervous system. This feature is an important contributory 
factor to the progression of circulatory dysfunction and 
the pathogenesis of HRS, which constitutes the last stage 
of the circulatory disturbances in cirrhosis[244,247,248]. Other 
systems are affected as well including: The femoral 
and brachial vessels (producing cramps), the immune 
system, the adrenal glands, and the vessels in the brain 
(playing a role in encephalopathy)[247,249]. 
The vasoconstrictive compensation in cirrhosis 
includes the renal vessels and negatively affects renal 
function, resulting in sodium and solute­free water 
retention, edema, and eventually renal failure. Patients 
with advanced cirrhosis exhibit a shift in the renal 
autoregulation curve, which means that for a given 
level of perfusion pressure, renal blood flow is lower 
compared to that of patients with compensated cirrhosis; 
a decrease in GFR leading to HRS ensues. HRS is almost 
exclusively of a functional nature and usually without 
discernable histologic abnormalities in the kidneys[242,245]. 
However, in some reports the kidneys of cirrhotic patients 
with presumed HRS showed histologic evidence of AKI. 
Immunologic mechanisms are apparently important in 
mediating the renal injury and hemodynamic factors do 
not operate in isolation[251]. 
HRS is classified into two subgroups, HRS 1 and 
HRS 2. The rate of deterioration of renal function is 
rapid, within 2 wk, in HRS 1 and slower in HRS 2, oc­
curring over several months[244]. HRS must routinely be 
differentiated from two other conditions that cause AKI 
frequently in cirrhotic patients, namely acute tubular 
necrosis and prerenal azotemia. AKI in cirrhosis carries 
a high risk for mortality[252], with HRS or acute tubular 
necrosis having substantially higher mortality rates 
compared to prerenal azotemia[252]. Urinary biomarkers 
can be helpful in differentiating between HRS and acute 
tubular necrosis. Urinary neutrophil gelatinase­associated 
lipocalin (NGAL) activity was shown to be highly accurate 
in identifying patients with acute tubular necrosis and was 
incorporated into a proposed diagnostic algorithm[253]. 
Other biomarkers that were shown to be useful in the 
diagnosis of acute tubular necrosis include interleukin­18 
(IL­18), albumin, trefoil­factor­3 (TFF­3) and glutathione­
S­transferase­π (GST­π)[253]. 
NGAL is not helpful in differentiating between pre­
renal azotemia and HRS[247]. Also, biochemical analytes 
indicative of tubular function do not distinguish between 
prerenal azotemia and HRS; in both conditions, the 
decrease in GFR is associated with intact tubular 
function as reflected by a very low urinary sodium con­
centration and high urine to plasma (U/P) creatinine 
ratio. The response of renal dysfunction to expansion of 
the intravascular space with colloid or saline solutions 
constitutes the key differentiating feature between 
the two conditions. Prerenal azotemia is reversed with 
adequate fluid replacement and no other measures. In 
contrast, reversal of HRS requires administration of fluid 
plus vasoconstrictors. 
In addition to pre­renal azotemia and acute tubular 
necrosis due to hypovolemia (bleeding, diarrhea, 
excessive use of diuretics), several other clinical conditions 
may cause AKI in patients with advanced cirrhosis. These 
conditions include: (1) Bacterial infections with or without 
septic shock (such as spontaneous bacterial peritonitis); 
(2) use of nephrotoxic medications such as non­steroidal 
anti­inflammatory drugs or aminoglycosides; (3) 
abdominal compartment syndrome from tense ascites; 
and (4) intrinsic renal diseases (hepatitis­B or C associated 
glomerulonephritis, glomerulonephritis in alcoholic 
cirrhosis)[240,244,252]. The initial management of cirrhotic 
patients with AKI should address all these conditions. 
This management is therefore complex, but depends 
primarily on accurate assessment of the status of EABV. 
Physical examination and invasive measurements, such as 
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central venous pressure, often do not reflect intravascular 
volume status. Point­of­care echocardiography can be 
effective in guiding the timing of large volume abdominal 
paracentesis and optimizing the hemodynamic status in 
decompensated cirrhotic patients with AKI, which in turn 
can improve venous return and promote recovery of renal 
function[254].
First­line treatment of patients with cirrhosis and 
ascites consists of sodium restriction and application of 
diuretics. However, the main thrust for preventing and 
managing HRS is directed towards expanding ECFV 
with albumin infusions and correcting the splanchnic 
vasodilatation by vasoconstrictors, including octreotide, 
sympathomimetic agents (i.e., midodrine), and vaso­
pressin analogues (i.e., terlipressin). Oral midodrine has 
been shown to improve clinical outcomes and survival in 
patients with refractory ascites[255]. In patients with stable 
hypotension, midodrine may improve splanchnic and 
systemic hemodynamic variables, renal function, and 
sodium excretion. In patients without HRS, midodrine 
was shown to increase urinary volume, urinary sodium 
excretion, and mean arterial pressure and was associated 
with a reduction in overall mortality[256]. 
Terlipressin and albumin administration can reverse 
HRS and reduce the associated short­term mortality 
rate[257,258]. Terlipressin alone is effective in reversing 
HRS in a smaller number of patients (40%­50%). 
In the REVERSE study, terlipressin plus albumin was 
associated with greater improvement in renal function 
vs albumin or terlipressin alone in patients with HRS­1, 
whereas rates of HRS reversal were similar with 
terlipressin or albumin alone[259]. 
Based on four small studies, norepinephrine appears 
to be an attractive alternative to terlipressin in the 
treatment of HRS, in part because it is associated with 
fewer adverse events[260]. Infusion of albumin plus 
norepinephrine may be beneficial in HRS 1[255]. Albumin 
has dose­dependent effects in both increasing survival 
and reducing complications in cirrhotic patients with 
HRS[261]. The beneficial effects of albumin infusion are 
not due solely to its oncotic properties. In patients 
with advanced cirrhosis, several albumin functions, 
such as binding of toxins, drugs and drug metabolites, 
are depressed because of molecular alterations of the 
compound, e.g., to oxidized albumin. Replacement of 
the altered albumin molecules by the infused albumin 
has beneficial effects[262]. Predictors of the clinical 
response to terlipressin and albumin treatment are 
the serum bilirubin and creatinine levels along with the 
increase in blood pressure and the presence of systemic 
inflammatory response syndrome[258]. 
Another approach to the management of HRS, 
namely “head­out” water immersion, has confirmed 
the importance of low EABV in this syndrome. Two 
studies have investigated water immersion as a means 
of increasing central blood volume in patients with 
HRS[241,263]. In both studies, water immersion resulted 
in marked natriuresis and diuresis, and a decrease in 
plasma levels of renin and aldosterone. In the study by 
Bichet et al[241], although a five­hour water immersion in 
one patient with HRS resulted in central blood volume 
expansion and a modest decrease in serum creatinine 
concentration, it did not reverse the HRS. In a study 
by Yersin et al[263], two patients with HRS underwent 
repeated two­hour daily courses of water immersion for 
a week; in both patients, significant decreases in serum 
creatinine concentration were noted. 
In a recent therapeutic algorithm for HRS 1, the use 
of the combination of octreotide, midodrine and albumin 
without vasoconstrictors was discouraged because of low 
efficacy[255]. The use of vasopressin for the treatment 
of HRS­1 was also not recommended, due to several 
adverse effects and the lack of randomized, clinical trials 
supporting this use[257]. Other treatments for HRS have 
also been assessed and include dopamine, transjugular 
intrahepatic portosystemic shunt, and renal and liver 
replacement therapy. However, current thinking is that 
liver transplantation in the only curative option and 
should be considered in all patients[247,257]. 
The evaluation of EABV in patients with cirrhosis, 
especially with regard to the differential diagnosis of 
AKI, is based on their response to infusion of albumin 
and vasopressors. Traditional laboratory techniques 
have also been employed for the evaluation of the 
status of fluid balance in these patients. The BNP and 
its prohormone (pro­BNP) are elevated in patients with 
cirrhosis as well as those with CHF, thereby rendering 
it difficult from a single plasma BNP measurement to 
accurately differentiate between ascites due to CHF 
and ascites due to cirrhosis[264]. Elevated plasma BNP 
confirms CHF with high probability, but is of limited 
value in evaluating EABV in cirrhosis[265,266].
Methods evaluating body composition have also 
been employed for evaluating fluid balance status in 
cirrhotic patien. BIA studies have been employed in 
evaluating the volume of the ascetic fluid[267] and the 
changes in ECFW/TBW in various parts of the body 
as cirrhosis progresses[267,268]. Further work is needed 
to evaluate the role of body composition analysis in 
assessing fluid balance in cirrhotic patients. 
CHF and cirrhosis both usually cause ECFV ex­
pansion. Whether a modest degree of ECFV expansion 
is beneficial in early compensated stages of CHF has 
yet to be determined. ECFV expansion is deleterious in 
advanced stages of CHF; however, a modest degree of 
ECFV expansion appears to be beneficial in cirrhosis. 
The treatment of advanced cirrhosis, especially HRS, is 
based on further ECFV expansion by means of albumin­
containing solutions. ECFV levels optimal for these 
conditions remain to be established. In addition to ECFV 
excesses, both advanced CHF and advanced cirrhosis 
are often associated with relative water excess leading 
to hypotonic hyponatremia. Unlike hypervolemia, 
which at least in cirrhosis may have beneficial effects, 
hyponatremia is an independent predictor of adverse 
outcomes in both CHF[269,270] and cirrhosis[271]. Current 
management guidelines call for aggressive treatment of 
hyponatremia in both clinical conditions[82]. 
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Sepsis
The definition of sepsis and the methods for determining 
its degree of severity have undergone changes recently. 
Two degrees of severity are currently recognized, namely 
sepsis and septic shock. The older degree “severe 
sepsis” was deemed redundant. Sepsis is defined as life­
threatening organ dysfunction secondary to a response 
to infection involving both pro­inflammatory and anti­
inflammatory immunological responses and reactions in 
non­immunological cardiovascular, neuronal, hormonal, 
metabolic, bio­energetic, and coagulation pathways[272]. 
Septic shock is a subset of sepsis characterized by 
profound circulatory, cellular, and metabolic abnormalities 
and a heightened mortality risk[272]. Severe hypotension 
and greatly elevated serum lactate levels are the defining 
criteria of septic shock.
Sepsis accounts for about 2% of all hospital admissions 
and 10% of intensive care unit (ICU) admissions in 
the United States[273]. Several organ systems develop 
severe dysfunction during sepsis, the respiratory and 
cardiovascular systems being the most commonly 
affected. Other frequently affected organ systems include: 
The central nervous system, kidneys, peripheral nervous 
system, muscles, gastro­intestinal tract, and thyroid 
gland[273]. The development of AKI in sepsis is associated 
with a 70% mortality rate[274].
The pathogenesis of sepsis involves different mech­
anisms that have been investigated by various teams 
of researchers[272­274]. Unraveling these mechanisms 
has led to novel strategies, some of which are still in the 
research stage, for managing sepsis[275]. In this review, 
we focus on fluid balance issues. Sepsis causes profound 
disturbances in at least three of the determinants of EABV 
listed in Table 5: Vascular capacity, cardiac output, and 
capillary endothelial barrier. Sepsis can be considered as 
the prototype of an acute illness causing life­threatening 
decreases in EABV. In sepsis, ECFV values above the 
normal range are associated with favorable outcomes. 
Increased vascular capacity is a primary cause of low 
EABV in sepsis. Pro­inflammatory cytokines released in 
sepsis cause arterial vasodilatation and decrease peri­
pheral vascular resistance. Several metabolic pathways 
mediate vasodilatation. Upregulation of the inducible 
nitric oxide synthase and profound release of nitric oxide 
is a potent vasodilatory pathway[274]. Vasodilatation is 
manifested primarily in the splanchnic vascular bed, 
the muscles and the skin, while the renal vascular bed 
exhibits vasoconstriction[274]. Compensatory mechanisms 
for vasodilatation include activation of the sympathetic 
nervous system and the renin­angiotensin­aldosterone 
axis, release of vasopressin, and increase in cardiac 
output[274]. Renal vasoconstriction results from high 
levels of the compensatory hormones which include 
catecholamines and vasopressin. 
One of the mechanisms for compensating for 
low EABV in sepsis is an increase in cardiac output. 
However, cardiac output may be depressed in severe 
septic episodes leading to decreased ejection fraction 
in approximately 50% of the cases[276]. Studies in a 
murine model also revealed adverse effects of sepsis on 
heart rate, heart rate variability and electrical impulse 
conduction[277]. Reversal of cardiac dysfunction in sepsis 
survivors after several days suggests that the mechanism 
of dysfunction was functional rather than structural[276,278]. 
However, structural cardiac abnormalities, including 
mononuclear cell infiltrates, edema, fibrosis, disruption 
of mitochondria, myocardial cell death and apoptosis 
were found in the hearts of humans or experimental 
animals dying from sepsis[279]. A variety of mechanisms 
leading to myocardial dysfunction in sepsis have been 
proposed[276,278,279]. Therapeutic interventions directed to 
specific mechanisms are at the stage of pre­clinical trials 
in experimental sepsis models[280]. 
Disruption of the blood capillary endothelial barrier 
is the third major mechanism leading to low EABV in 
sepsis. Starling forces regulate fluid transfers between 
the intravascular and interstitial compartment and play 
an important role in the maintenance of the intravascular 
blood volume and EABV. In animal studies reviewed by 
Schrier and Wang[274], vasodilatation caused albumin 
and fluid transfer from the intravascular into the 
interstitial compartment. Generalized capillary protein 
leakage was documented in septic patients by Ishihara 
and coinvestigators[281]. The endothelial barrier defect 
is not the exclusive result of arterial vasodilatation. 
A variety of mediators of endothelial barrier damage 
in sepsis, including the complement components Ca 
and C5a, bradykinin, platelet activating factor (PAF), 
pro­inflammatory cytokines, and many others have 
been identified[282,283]. Endothelial barrier disruption 
is considered a key step in the development of septic 
shock[283]. 
Collectively, vasodilatation, myocardial dysfunction, 
and impairment of the endothelial barrier lead to de­
crease in EABV and render imperative the need for 
administration of large volumes of fluid and vasocon­
strictors, which are mainstays of treatment in sepsis. 
However, impaired cardiac and endothelial barrier 
function increase the risks of fluid administration in 
septic patients[274,284] and narrow its therapeutic margins. 
Recent therapeutic trials and meta­analyses[285­294] have 
addressed the issue of the volume of fluids administered 
to septic patients among other issues. 
A prospective randomized trial of aggressive treat­
ment by infusion of fluids based on invasive monitoring 
of central venous pressure in septic patients prior to 
their admission to the ICU showed advantages in 
survival and improvement in important biochemical 
parameters including central pressure oxygen saturation, 
serum lactate concentration and metabolic acid­base 
values[285]. Subsequently, three large prospective 
randomized studies compared goal­directed early (pre­
ICU) resuscitation and routine management of septic 
shock[286­288]. In all three studies, patients assigned to 
early goal­directed care routinely received larger volumes 
of fluids and higher doses of vasoconstrictors than those 
assigned to routine care. No difference in mortality and 
most other secondary outcomes was noted between the 
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shock is not associated with early (28 d) or late (90 d) 
mortality improvement[289].
Fluid balance during treatment of sepsis or septic 
shock was addressed in three recent reports. One 
study found no difference in volume of fluid gained 
during treatment of septic shock between surviving 
and deceased patients[290]. The second study found 
significantly lower mortality in patients with sepsis 
or septic shock receiving less than 5 L than in those 
receiving more than 5 L of fluids in the first day of 
treatment and an increase in mortality by 2.3% for each 
liter of administered fluid in excess of 5 L[291]. The third 
study analyzed risks for mortality from sepsis associated 
with a completion within three hours of a protocol calling 
for blood cultures, administration of antibiotics and 
administration of 30 mL of crystalloids per kilogram. This 
study reported an increased risk for longer waiting until 
administration of antibiotics, but not for longer time to 
completion of the fluid bolus[292]. 
Finally, two randomized studies addressed two 
other issues related to fluid balance and EABV during 
treatment of septic shock. The first study found similar 
mortality rates in patients with targeted mean arterial 
blood pressure of 80 to 85 mmHg and those with 
targeted pressure of 60 to 65 mmHg[293]. Mean fluid 
volume administration was similar in the two groups 
while the higher blood pressure group received higher 
doses of norepinephrine and for a longer time. The 
second study found similar mortality rates in patients 
with targeted blood hemoglobin level above 9 g/dL 
and those with targeted level above 7 g/dL[294]. The 
international guidelines for management of sepsis and 
septic shock recommend a minimal initial intravenous 
crystalloid fluid bolus of 30 mL/kg within the first 
three hours followed by additional fluid administration 
guided by hemodynamic monitoring and maintenance 
of mean arterial blood pressure above 65 mmHg by 
vasoconstrictors as needed[295]. The guidelines highlight 
all three recommendations as “strong” and the quality 
of evidence as “weak” for the first recommendation, 
“best practice evidence” for the second and “moderate” 
for the third.
Infusion of large volumes of fluid is one of the key 
therapeutic modalities in sepsis and septic shock; however, 
the literature provides ample evidence indicating that the 
safety margin of fluid infusion in sepsis is narrow. The 
optimal level of volume expansion will need further research 
to be determined. The need for volume replacement in 
sepsis is not determined by measurements of ECV, but by 
clinical, laboratory and hemodynamic criteria. Calculation 
of blood volume, by adding plasma volume measurements 
obtained by dilution of injected albumin labelled with 
radioactive iodine (131I­albumin) and red cell mass 
computed from either hematocrit and plasma volume (Blood 
volume = plasma volume/1∣Hematocrit), or measured 
simultaneously with plasma volume by injected red blood 
cells (RBCs) labelled with radioactive chromium (51Cr­RBC) 
has found wider application than the measurement of TBW 
or ECV in critically ill patients with conditions leading to 
blood loss[296,297]. 
Nephrotic syndrome
Heavy albuminuria, hypoalbuminemia and pronounced 
salt retention leading to ECFV expansion and edema, but 
typically not to hypertension, characterize the nephrotic 
syndrome. The cardinal complaint of patients suffering 
from nephrotic syndrome is edema[298]. The pathogenesis 
of edema formation has been disputed[299]. Two theories, 
the underfill and overflow or overfill theories, explaining 
the fundamental mechanism of salt retention and 
edema formation in nephrotic syndrome have been 
proposed[300,301]. The underfill theory places the focus of 
salt retention on the nephrotic hypoalbuminemia which 
causes through Starling forces decreased blood volume 
and EABV and stimulation of neurohumoral pathways 
leading to renal salt and water retention[300,302]. A subset 
of patients with severe nephrotic syndrome and profound 
hypoalbuminemia exhibit elevated serum levels of 
indicators of hypovolemia, including vasopressin, renin, 
aldosterone and norepinephrine; “head­out” water 
immersion of nephrotic patients with these features 
resulted in pronounced natriuresis and diuresis and 
substantial decreases in the levels of all four indicators of 
hypovolemia[303]. Decreases in interstitial colloid­osmotic 
pressure accompanying decreases in plasma albumin 
concentration and colloid­osmotic pressure modulate the 
loss of intravascular fluid into the interstitial compartment 
in nephrotic syndrome[304]. 
The overflow theory states that patients with 
nephrotic syndrome have an expanded plasma volume, 
and that the retention of sodium leading to edema 
formation in these patients is the result of an intrinsic 
defect in renal salt excretion. The first evidence against 
the underfill theory was provided by Meltzer et al[305] 
who noticed that serum renin and aldosterone levels 
were not elevated in a subset of patients with nephrotic 
syndrome. Other important observations arguing against 
the underfill theory include the following: (1) Animals 
and humans with congenital analbuminemia rarely 
develop edema[306,307]; (2) blood volume is increased 
in a subset of edematous patients with the nephrotic 
syndrome[308]; (3) volume expansion with hyperoncotic 
albumin in edematous patients with nephrotic syndrome 
and various underlying renal histologic pictures, including 
minimal change disease, results in normal suppression 
of plasma renin activity and aldosterone, without 
significantly increasing urinary sodium excretion[309]; (4) 
medications blocking the renin­angiotensin­aldosterone 
system (RAAS), such as angiotensin­converting enzyme 
(ACE) inhibitors, do not increase natriuresis in nephrotic 
patients[310]; (5) adrenalectomy does not prevent 
edema formation in laboratory animals with nephrotic 
syndrome[311]; and (6) natriuresis in the recovery phase 
of nephrotic syndrome in children starts before serum 
albumin is normalized[312]. These observations suggested 
that the renal retention of sodium salts in some patients 
with nephrotic syndrome results not from low EABV, but 
from a primary renal retention of sodium[313,314]. 
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Ichikawa et al[315] reported primary renal retention 
of salt in a unilateral model of puromycin­induced nep­
hrotic syndrome in rats. Subsequently, Kim et al[316] 
demonstrated increased expression and apical targeting 
of the epithelial sodium channel (ENaC) in the distal 
convoluted tubule, connecting tubule, and collecting duct 
of rats with puromycin­induced nephrotic syndrome. 
Increased synthesis of the sodium­potassium ATPAse 
(Na,K­ATPase) was also observed in the collecting ducts 
of rats with puromycin­induced nephrotic syndrome[317]. 
Serine proteases, which are present in high concentrations 
in the glomerular filtrate of nephrotic patients, play a 
major role in the activation of ENaC by cleaving certain 
channel­protein subunits and removing certain inhibitory 
peptides from the channel thus increasing its open 
probability[318]. A landmark study by Svenningsen et al[319] 
showed that urine from laboratory animals and patients 
with nephrotic syndrome can activate ENaC and promote 
sodium retention. In this study, mass­spectrometry 
analysis identified plasmin, an abnormally filtered enzyme, 
as the serine protease responsible for ENaC activation. 
The widely accepted current view is that sodium 
retention develops in all subtypes of the nephrotic 
syndrome because of ENaC activation in the collecting 
ducts regardless of EABV[320,321]. Other mechanisms, 
including a proposed increase in the permeability of blood 
capillaries[321,322], decrease in the renal response to atrial 
natriuretic peptide (ANP), decreased conversion of pro­
ANP to ANP in the kidneys, and decreased expression 
of nitric oxide synthase in the kidneys[323], are also likely 
contributors to salt retention and edema formation in the 
nephrotic syndrome. Underfilling represents an additional 
mechanism of edema formation in some nephrotic 
patients[314]. Hypovolemia and underfilling are pronounced 
in nephrotic subjects with very low serum albumin levels, 
e.g., children with minimal change disease[323]. BIA 
studies have been employed in assessing fluid balance 
in patients with the nephrotic syndrome[324­326]. Figure 5 
shows changes in EABV and ECF in the chronic conditions, 
including CHF, cirrhosis and nephrotic syndrome, discussed 
in this report.
CONCLUSION
The traditional concepts of body fluid balance encompass 
the regulation and perturbations of the relation between 
TBW and effective body solute (tonicity), and the 
regulation, measurement, and disturbances of ECFV. 
Severe acute and chronic illnesses cause disturbances 
that affect both fluid balance concepts. However, while 
the disturbances in tonicity have always adverse effects 
and require aggressive treatment, modest excesses in 
ECFV can be beneficial in some illnesses (e.g., cirrhosis, 
sepsis) and represent targets of the fluid management. 
The optimal ECFV in these illnesses is greater than the 
normal ranges of ECFV in healthy individuals because 
disease states produce changes in several factors that 
interact with ECFV in regulating EABV. These other 
factors are subjects of intense research and constitute 
therapeutic targets along with fluid treatment of ECFV. It 
is important to distinguish between fluid retention that 
results from low EABV, as in CHF or cirrhosis, and fluid 
retention that results from either low EABV or primary 
renal salt and water mechanisms, as in nephrotic 
syndrome. The traditional methods for measuring ECFV 
are associated with greater sources of error in patients 
with severe illness than in normal individuals. The man­
agement of fluid balance in patients with severe illness 
clearly needs further research. Two key questions 
regarding fluid balance should be addressed in these 
patients: (1) Are factors other than ECFV affecting EABV 
(Table 5) disturbed causing, in addition to the need for 
their proper management, the need for ECFV values 
different from the normal values? (2) If fluid retention 
is a feature of these illnesses, is it a consequence of 
decreased EABV from a disturbance of the factors shown 
in Table 4 or of primary renal retention of salt? For these 
reasons, severe illness with fluid disturbances justifies a 
separate concept of body fluid balance. 
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